Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ciforadenant · CPI-444, V-81444

Small molecule · Antagonist of adenosine A2A receptor (ADORA2A) · developed by Corvus Pharmaceuticals

Phase 1 Most advanced trial (none active)
CRVS Developer
3 Registered trials

What is Ciforadenant?

Ciforadenant is an oral small molecule that binds adenosine A2A receptors on immune cells, including T-lymphocytes, natural killer cells, macrophages and dendritic cells. It blocks tumor-released adenosine from acting on these receptors, which is intended to reverse adenosine-induced immunosuppression in the tumor microenvironment. It is studied in renal cell cancer, metastatic castration-resistant prostate cancer and multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CPI-444, V-81444
Drug type
Small molecule
Targets
adenosine A2A receptor (ADORA2A)
Mechanism
Antagonist of adenosine A2A receptor (ADORA2A)
Pathways
adenosine-mediated immunosuppression, anti-tumor immune response
Therapy area
Oncology
Developer
Corvus Pharmaceuticals, Inc. (CRVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
8KFO2187CP

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04280328 Phase 1 Multiple Myeloma Completed CRVS
NCT03237988 Phase 1 Healthy Subjects Completed CRVS
NCT02655822 Phase 1 Renal Cell Cancer Completed CRVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy SubjectsMetastatic Castration Resistant Prostate CancerMultiple MyelomaRenal Cell Cancer

Other drugs acting on ADORA2A

More from Corvus Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRVS page.

Follow CRVS, the company behind Ciforadenant

See CRVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.